SEC Form 4 · accession 0001213900-16-019206
ORAMED PHARMACEUTICALS INC. · ORMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin Rakin
Director
Period of report
Dec 5, 2016
Accepted (ET)
Dec 7, 2016 · 11:11 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001176309
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 5, 2016 | A | 2,300 | $6.3761 | A | 11,761 | D | |
| Common StockF2 | Dec 6, 2016 | A | 3,300 | $6.5948 | A | 15,061 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $6.36 to $6.39. The price reported above in Column 4 of Table I reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer complete information regarding the number of shares and prices at which each of the individual transactions was effected.
- F2This transaction was executed in multiple trades at prices ranging from $6.40 to $6.65. The price reported above in Column 4 of Table I reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer complete information regarding the number of shares and prices at which each of the individual transactions was effected.